A Phase I/II Study of Intensive-Dose Etoposide, Topotecan and Carboplatin (ETC) Followed by Autologous Stem Cell Rescue in Chemosensitive Ovarian Cancer Patients With Either Minimal Residual Disease or at First Relapse
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin; Cyclophosphamide; Etoposide; Paclitaxel; Topotecan
- Indications Ovarian cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 26 Sep 2012 Biomarkers information updated
- 25 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Sep 2005 New trial record.